-
-
-
-
-
-
-
Savara submits BLA for MOLBREEVI with FDA priority review set for August
-
-
-
-
-
-
-
Savara resubmits drug application to FDA with new manufacturer
-
-
-
-
-
-
-
Savara (SVRA) PT Raised to $11 at Citizens on Molbreevi Demand Prospects
-
-
-
-
-
-
-
Savara (SVRA) Misses Q2 EPS by 2c
-
-
-
-
-
-
-
Savara (SVRA) Misses Q1 EPS by 2c
-
-
-
-
-
-
-
Savara (SVRA) Completes Submission of the BLA for MOLBREEVI
-
-
-
-
-
-
-
Savara (SVRA) Reports In-Line Q3 EPS
-
408,792 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

